Media coverage about Tabula Rasa HealthCare (NASDAQ:TRHC) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tabula Rasa HealthCare earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.9259320332371 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have effected Accern’s analysis:

Several equities research analysts have commented on the stock. Oppenheimer increased their price objective on shares of Tabula Rasa HealthCare from $65.00 to $86.00 and gave the company an “outperform” rating in a research note on Thursday. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th. Citigroup increased their price objective on shares of Tabula Rasa HealthCare from $57.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Piper Jaffray Companies increased their price objective on shares of Tabula Rasa HealthCare to $71.00 and gave the company an “overweight” rating in a research note on Wednesday, August 8th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $70.00 price objective on shares of Tabula Rasa HealthCare in a research note on Wednesday, August 8th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and a consensus target price of $58.91.

NASDAQ:TRHC opened at $83.34 on Friday. The company has a quick ratio of 0.33, a current ratio of 0.36 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -2,083.50, a PEG ratio of 6.14 and a beta of 2.03. Tabula Rasa HealthCare has a 52 week low of $19.62 and a 52 week high of $85.26.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Tuesday, August 7th. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.12. The firm had revenue of $48.60 million during the quarter, compared to analyst estimates of $46.73 million. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%. equities analysts forecast that Tabula Rasa HealthCare will post 0.52 earnings per share for the current year.

In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $60.28, for a total value of $482,240.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 48,000 shares of company stock valued at $3,061,440. Company insiders own 14.00% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Further Reading: Penny Stocks, Risk and Reward Factors

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.